David Salzman
Chief Executive Officer Gatehouse Bio
David W. Salzman, PhD is the CEO of Gatehouse Bio, where he leads the R&D of precision microRNA-based therapeutics using multi-modal datasets and artificial intelligence. He previously held leadership roles at MiraDx and Biogen, where his work contributed to the development of the ProsTOX and PrevIOTox diagnostics and QALSODY, an FDA-approved antisense oligonucleotide therapy for SOD1-mutated ALS. He earned his PhD in Molecular Biology and serves as a Business Advisor to the Harvard Institute for RNA Medicine.
Seminars
Thursday 20th August 2026
AI-Driven microRNA Target Discovery for CNS: Unlocking Precision Oligonucleotide Therapeutics
4:00 pm
- Leveraging large-scale, translational multi-omics datasets to identify novel microRNA isomiRs associated with CNS disease biology and progression
- Applying AI-driven modelling to stratify patients and uncover precision oligo targets linked to distinct disease trajectories
- Enabling end-to-end translation from human data to preclinical models, supporting target validation, biomarker development, and therapeutic discovery
